The RefinedScience platform combines unique institutional access to clinical data and patient tissue with AI analysis tools and biological validation — all on one integrated system, spanning 7 oncology indications.
The RefinedScience Platform
What AI alone cannot provide. A platform designed to connect biological discovery with biological reality
Deep Clinical Data Infrastructure
Structured longitudinal patient data
Treatment history, outcomes, toxicities
Real-world and trial-linked datasets
External control capabilities
From Data to Decision Leverage
Target Identification and Validation
Identify and validate biologically meaningful targets using integrated clinical outcomes and high-resolution human tissue data.
External Control Analyses
Leverage structured longitudinal clinical datasets to generate regulator-aware external control arms that enhance trial interpretability.
Patient Stratification Refinement
Define clinically relevant patient subpopulations by linking molecular heterogeneity to real-world treatment response.
Indication Expansion
Uncover new therapeutic opportunities by mapping molecular signatures to adjacent disease populations with shared biology.
Trial Design Optimization
Strengthen trial design through data-informed endpoint selection, inclusion criteria, and predictive risk stratification.
Asset Repositioning
Re-evaluate existing assets through integrated human data to clarify responder populations, refine strategy, and improve development decisions.
Built for Oncology. Designed to Scale.
Our platform integrates clinical and molecular data in a way that is extensible across disease areas, creating long-term optionality while maintaining near-term scientific focus.
Let’s Advance Smarter Drug Development
Whether you are seeking decision-ready insight, structured clinical data collaboration, or joint asset development, RefinedScience partners with teams committed to improving drug development outcomes.